Bleakley Financial Group, LLC Immunity Bio, Inc. Transaction History
Bleakley Financial Group, LLC
- $3.32 Trillion
- Q4 2024
A detailed history of Bleakley Financial Group, LLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Bleakley Financial Group, LLC holds 14,095 shares of IBRX stock, worth $44,963. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,095
Previous 15,943
11.59%
Holding current value
$44,963
Previous $59.3 Million
39.16%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding IBRX
# of Institutions
208Shares Held
70.1MCall Options Held
1.64MPut Options Held
1.31M-
Vanguard Group Inc Valley Forge, PA16.9MShares$53.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$36.4 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$27.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$12.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$7.17 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.28B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...